Clinical trials: Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00687674
- Testing
- dexamethasone, sorafenib tosylate, Lenalidomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic